# Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

> **NCT04006847** · PHASE1,PHASE2 · TERMINATED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Chronic Myeloid Leukemia, Chronic Phase

## Interventions

- **DRUG:** Eicosapentaenoic Acid
- **DRUG:** Tyrosine kinase inhibitor

## Key facts

- **NCT ID:** NCT04006847
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-14
- **Primary completion:** 2021-05-21
- **Final completion:** 2021-05-21
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Product complaint
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006847, "Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04006847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*